文献速递浆细胞疾病

维奈克拉靶向治疗复发/难治性t(11;14)多发性骨髓瘤的疗效

Efficacy of venetoclax as targeted therapy for relapsed/refractory t(11;14) multiple myeloma.
PubMed 文献 · Blood · 2017-10-10

这项1期研究纳入66例复发/难治性多发性骨髓瘤患者,接受维奈克拉单药治疗(剂量递增至1200 mg及安全性扩展)。总体缓解率21%(14/66),≥非常好的部分缓解率15%;46%伴t(11;14)的患者中缓解率40%、≥非常好的部分缓解率27%,且缓解与较高的BCL2:BCL2L1和BCL2:MCL1 mRNA表达比值相关。

要点

  • 维奈克拉单药在复发/难治性多发性骨髓瘤中总体缓解率21%(14/66)。
  • 伴t(11;14)患者缓解率40%,≥非常好的部分缓解率27%。
  • 缓解与较高的BCL2:BCL2L1和BCL2:MCL1 mRNA表达比值相关。

核心结论

  • 维奈克拉单药每日剂量至1200 mg具有可接受的安全性,并在复发/难治性多发性骨髓瘤中显示单药抗骨髓瘤活性,主要见于伴t(11;14)异常及BCL2家族表达谱有利的患者。

研究设计与样本

  • 1期研究,纳入66例复发/难治性多发性骨髓瘤患者,其中剂量递增队列30例、安全性扩展36例。
  • 患者先接受2周每周剂量递增导入,随后每日维奈克拉300、600、900或1200 mg(剂量递增队列)或1200 mg(安全性扩展)。
  • 疾病进展时可加用地塞米松。

主要发现

  • 患者既往接受中位5线治疗(范围1-15线);61%为硼替佐米和来那度胺双难治,46%伴t(11;14)。
  • 总体缓解率21%(14/66),15%达到≥非常好的部分缓解;大多数缓解(12/14,86%)见于伴t(11;14)患者。
  • 伴t(11;14)患者中缓解率40%,27%达到≥非常好的部分缓解。
  • 生物标志物分析证实,维奈克拉缓解与较高的BCL2:BCL2L1和BCL2:MCL1 mRNA表达比值相关。

关键数值与推荐

  • 最常见不良事件为轻度胃肠道症状:恶心47%、腹泻36%、呕吐21%。
  • 最常见的3/4级事件为血细胞减少:血小板减少32%、中性粒细胞减少27%、贫血23%、白细胞减少23%。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Venetoclax is a selective, orally bioavailable BCL-2 inhibitor that induces cell death in multiple myeloma (MM) cells, particularly in those harboring t(11;14), which express high levels of BCL-2 relative to BCL-XL and MCL-1. In this phase 1 study, patients with relapsed/refractory MM received venetoclax monotherapy. After a 2-week lead-in with weekly dose escalation, daily venetoclax was given at 300, 600, 900, or 1200 mg in dose-escalation cohorts and 1200 mg in the safety expansion. Dexamethasone could be added on progression during treatment. Sixty-six patients were enrolled (30, dose-escalation cohorts; 36, safety expansion). Patients received a median of 5 prior therapies (range, 1-15); 61% were bortezomib and lenalidomide double refractory, and 46% had t(11;14). Venetoclax was generally well tolerated. Most common adverse events included mild gastrointestinal symptoms (nausea [47%], diarrhea [36%], vomiting [21%]). Cytopenias were the most common grade 3/4 events, with thrombocytopenia (32%), neutropenia (27%), anemia (23%), and leukopenia (23%) reported. The overall response rate (ORR) was 21% (14/66), and 15% achieved very good partial response or better (≥VGPR). Most responses (12/14 [86%]) were reported in patients with t(11;14). In this group, ORR was 40%, with 27% of patients achieving ≥VGPR. Biomarker analysis confirmed that response to venetoclax correlated with higher BCL2:BCL2L1 and BCL2:MCL1 mRNA expression ratios. Venetoclax monotherapy at a daily dose up to 1200 mg has an acceptable safety profile and evidence of single-agent antimyeloma activity in patients with relapsed/refractory MM, predominantly in patients with t(11;14) abnormality and those with a favorable BCL2 family profile. Registered at www.clinicaltrials.gov: #NCT01794520.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Kumar S, Kaufman JL, Gasparetto C, et al. Efficacy of venetoclax as targeted therapy for relapsed/refractory t(11;14) multiple myeloma. Blood. 2017. PMID: 29018077. doi:10.1182/blood-2017-06-788786

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。